Furthermore, it is worth mentioning that there is a similar approach that is utilized to boost the bioavailability of anti-viral drugs such as nirmatrelvir for COVID-19 (Paxlovid) and several anti-HIV drugs, where ritonavir is used as a CYP3A inhibitor [22]. The gene discussed is CYP3A4; the disease is COVID-19.